Advertisement
Drug Pipeline
Subscribe to Drug Pipeline
View Sample

FREE Email Newsletter

Daily news and top headlines for drug research professionals

Bayer Extends Xarelto Investigation to 275,000 Patients

September 2, 2014 10:24 am | News | Comments

Bayer HealthCare and its development partner Janssen Research & Development LLC announced an expansion of the global clinical development program for the oral Factor Xa inhibitor rivaroxaban for the prevention of potentially deadly blood clots in patients at risk of arterial thromboembolism. Read more...

Novo Nordisk Discontinues Inflammatory Disorder Activities

September 2, 2014 10:00 am | News | Comments

Novo Nordisk announced a decision to discontinue all its research and development (R&D) activities within inflammatory disorders. Read more...                              

EC Approves Allergan's Ozurdex for DME

September 2, 2014 9:52 am | News | Comments

Allergan Inc. announced that the European Commission has extended the Marketing Authorization for Ozurdex to treat adult patients with visual impairment due to diabetic macular edema (DME). Read more...              

Advertisement

Heart Failure Drug Cuts Deaths, Hospitalizations by 20%

September 2, 2014 9:44 am | News | Comments

A new study reports one of the biggest potential advances against heart failure in more than a decade— a first-of-a-kind, experimental drug that lowered the chances of death or hospitalization by about 20%. Read more...          

Drug-Delivery Vehicle Could Limit Spread of HIV, AIDS

August 29, 2014 2:00 pm | News | Comments

A unique method for delivering compounds that could positively impact the global battle against HIV and AIDS may be possible, according to new research. Read more...                         

Researchers Investigating New MS Treatment

August 28, 2014 2:00 pm | News | Comments

A new treatment under investigation for multiple sclerosis (MS) is safe and tolerable in Phase 1 clinical trials, according to a new study. The Phase 1 studies were the first to test the drug candidate in humans. Read more...     

New Drug Ups OS in Stage III Colon Cancer

August 28, 2014 2:00 pm | News | Comments

A subset of patients with Stage III colon cancer had improved survival rates when treated with irinotecan-based therapy, according to a new study. Read more...                          

HIV Drug Dosage May Be Ineffective for African-Americans

August 28, 2014 2:00 pm | News | Comments

Many African-Americans may not be getting effective doses of the HIV drug maraviroc, a new study suggests. The initial dosing studies, completed before the drug was licensed in 2007, included mostly European-Americans, who generally lack a protein that is key to removing maraviroc from the body. Read more...

Advertisement

GSK-NIH Ebola Vaccine to Enter Safety Testing

August 28, 2014 2:00 pm | by Seth Borenstein, AP Science Writer | News | Comments

Federal researchers next week will start testing humans with an experimental vaccine to prevent the deadly Ebola virus. The NIH announced today that it is launching the safety trial on a vaccine developed by the agency's National Institute of Allergy and Infectious Diseases and GSK. Read more...

Compound Promises Relief for Inflammatory Pain

August 28, 2014 2:00 pm | News | Comments

Researchers have discovered that a compound they developed could potentially serve as a painkiller, with particular utility for East Asians with an alcohol-metabolizing enzyme mutation. Read more...                

Two-Drug Combo Speeds Wound Healing, Reduces Scar Tissue

August 28, 2014 9:53 am | News | Comments

A combination of two drugs already approved by the U.S. Food and Drug Administration for different applications reduces wound healing time by one-quarter and significantly decreases scar tissue in mice and rats, researchers report. Read more...     

FDA Approves Generic Megace from TWi

August 28, 2014 9:45 am | News | Comments

TWi Pharmaceuticals Inc. announced that it has received final approval from the FDA on its Abbreviated New Drug Application for megestrol acetate 125mg/ml oral suspension, the generic equivalent to Par Pharmaceutical's Megace ES. Read more...   

Daiichi Sankyo Signs Hep B Vaccine Agreement

August 28, 2014 9:40 am | News | Comments

Daiichi Sankyo Co. Ltd. announced that it has signed a cooperative sales agreement with The Chemo-Sero-Therapeutic Research Institute  for its recombinant adsorbed hepatitis B vaccine (yeast-derived), Bimmugen. Read more...       

Advertisement

FDA Clears Asterias to Begin Stem Cell Trial

August 27, 2014 3:08 pm | News | Comments

Asterias Biotherapeutics Inc. has received clearance from the FDA to initiate a Phase 1/2a clinical trial of its product, AST-OPC1, in patients with complete cervical spinal cord injury. Read more...               

Potential Therapy for Sudan Ebola Strain May Contain Future Outbreaks

August 27, 2014 2:45 pm | News | Comments

Ebola is a rare, but deadly disease that exists as five strains, none of which have approved therapies. One of the most lethal strains is the Sudan ebolavirus (SUDV). In a new study, researchers report a possible therapy that could someday help treat patients infected with SUDV. Read more...

Amgen Heart Failure Drug Gets Priority Review

August 27, 2014 2:32 pm | News | Comments

Amgen announced the FDA has granted priority review designation for ivabradine for the treatment of chronic heart failure (HF). Ivabradine is an oral drug that inhibits the If current ("funny" current) in the sinoatrial node. Read more...   

Compound Suppresses Binge Eating in Mice

August 27, 2014 2:26 pm | News | Comments

Researchers found that the hormone estrogen can specifically trigger brain serotonin neurons to inhibit binge eating, which affects about 5 to 10 percent of U.S. adults, in female mice. Read more...               

Drug Promising as Potential Anemia Treatment

August 27, 2014 2:21 pm | News | Comments

An experimental drug designed to help regulate the blood’s iron supply shows promise as a viable first treatment for anemia of inflammation, according to results from the first human study of the treatment. Read more...         

Merck Serono Breaks Ground on New China Facility

August 27, 2014 11:09 am | News | Comments

Merck Serono, the biopharmaceutical division of Merck, held the groundbreaking ceremony for its new pharmaceutical manufacturing facility in Nantong, China. Read more...                       

EC Approves BMS Drug as Hep C Combo Treatment

August 27, 2014 11:03 am | News | Comments

Bristol-Myers Squibb Co. announced that the European Commission has approved Daklinza (daclatasvir) for use in combination with other medicinal products across genotypes 1, 2, 3 and 4 for the treatment of chronic hepatitis C virus infection in adults. Read more...

Targeted Neuroblastoma Therapy One Step Closer

August 27, 2014 10:52 am | News | Comments

Researchers have uncovered new targets for therapy in the childhood cancer neuroblastoma, bringing hope for the development of novel treatments. Read more...                           

New Statin Guidelines are an Improvement, Study Shows

August 26, 2014 3:18 pm | News | Comments

New national guidelines can improve the way statin drugs are prescribed to patients at risk for cardiovascular disease, a study has found. Read more...                             

FDA Approves Additional Promacta Indication

August 26, 2014 3:14 pm | News | Comments

GSK announced that the FDA has approved a supplemental New Drug Application for the once-daily use of Promacta (eltrombopag) in patients with severe aplastic anemia (SAA) who have had an insufficient response to immunosuppressive therapy (IST). Read more...

Alkermes Launches Phase 1 Pain Treatment Study

August 26, 2014 3:08 pm | News | Comments

Alkermes plc announced the initiation of a Phase 1 clinical study of ALKS 7106, a proprietary, novel, oral, small-molecule drug candidate for the treatment of pain. Read more...                       

Kite Pharma's Lymphoma Drug Excels in Trial

August 26, 2014 3:03 pm | News | Comments

Shares of Kite Pharma surged before markets opened Tuesday after the drug developer detailed promising results for its most advanced product, a potential treatment for an aggressive form of non-Hodgkin's lymphoma. Read more...       

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading